In a recent TreatmentTrends© study with EU5 dermatologists, BioTrends Research Group, LLC finds that there has been a slight increase in the use of biologics in all of the EU5 countries except Italy, where usage has remained constant. Future prescribing habits will see moderate increases in prescribing for both Janssen's Stelara and Abbott's Humira, but this increase will be at the expense of Amgen's Enbrel and other biologic agents.